Encision Reports Third Fiscal Quarter Revenue Increase of 32% Over Prior Year's Third Fiscal Quarter
23 Gennaio 2007 - 1:00PM
PR Newswire (US)
BOULDER, Colo., Jan. 23 /PRNewswire-FirstCall/ -- Encision Inc.
(AMEX:ECI), a medical device company owning patented surgical
technology that is emerging as a standard of care in
minimally-invasive surgery, reported its financial results for its
third fiscal quarter ended December 31, 2006. Revenue for the third
fiscal quarter ended December 31, 2006 was $2.79 million,
representing a 32% increase over revenue of $2.12 million for the
prior fiscal year's third quarter. The Company recorded a net loss
of $49 thousand or $.01 per share for the third quarter of fiscal
year 2007 compared to a net loss of $154 thousand or $.02 per share
for the third quarter of fiscal year 2006. Net loss for the third
quarter of fiscal year 2007 includes stock-based compensation
expense of $44 thousand, or $.01 per share, due to the
implementation of SFAS 123(R). Financial results prior to fiscal
year 2007 did not include stock-based compensation expense. Net
loss for the third quarter of fiscal year 2007 also includes a
one-time expense of $73 thousand, or $.01 per share, relating to
the costs of obtaining equity capital financing, a project that was
subsequently abandoned after the Company obtained a $2 million line
of credit facility from SVB Silicon Valley Bank. Gross profit
margin for the third quarter of fiscal year 2007 was 62% as
compared to 60% for the third quarter of fiscal year 2006. Revenue
for the nine months ended December 31, 2006 was $8.2 million,
representing a 22% increase over revenue of $6.7 million for the
prior fiscal year's nine months. The Company recorded net income of
$87 thousand or $.01 per share for the nine months of fiscal year
2007 compared to a net loss of $297 thousand or $.05 per share for
the nine months of fiscal year 2006. Net income for the nine months
of fiscal year 2007 includes stock-based compensation expense of
$138 thousand, or $.02 per share, due to the implementation of SFAS
123(R). Financial results prior to fiscal year 2007 did not include
stock-based compensation expense. Net income for the nine months of
fiscal year 2007 also includes a one-time expense of $73 thousand,
or $.01 per share, relating to the costs of obtaining equity
capital financing, a project that was subsequently abandoned after
the Company obtained a $2 million line of credit facility from SVB
Silicon Valley Bank. Gross profit margin for the nine months of
fiscal year 2007 was 63% as compared to 60% for the nine months of
fiscal year 2006. "I am pleased with our 32% revenue growth over
the prior year's third quarter revenue," said Jack Serino,
President and CEO of Encision Inc. "In the third quarter we
obtained a $2 million line of credit facility that will enable us
to offer a disposable instrument option for each major reusable
product and to increase our number of direct sales territories. We
began hiring for these programs during the quarter." Encision Inc.
designs, develops, manufactures and markets innovative surgical
devices that allow surgeons to optimize technique and patient
safety during a broad range of surgical procedures. Based in
Boulder, Colorado, the Company pioneered the development of
patented AEM(R) Laparoscopic Instruments to improve electrosurgery
and reduce the chance for patient injury in minimally invasive
surgery. In accordance with the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995, the Company notes
that statements in this press release and elsewhere that look
forward in time, which include everything other than historical
information, involve risks and uncertainties that may cause actual
results to differ materially from those indicated by the
forward-looking statements. Factors that could cause the Company's
actual results to differ materially include, among others, its
ability to increase revenues through the Company's distribution
channels, insufficient quantity of new account conversions,
insufficient cash to fund operations, scale up production to meet
delivery obligations, delay in developing new products and
receiving FDA approval for such new products and other factors
discussed in the Company's filings with the Securities and Exchange
Commission. CONTACT: Marcia McHaffie, Encision Inc., 303-444-2600,
ENCISION INC. Condensed Statements of Operations (Unaudited)
(Amounts in thousands, except per share information) Three Months
Ended Nine Months Ended December 31, December 31, December 31,
December 31, 2006 2005 2006 2005 Revenue $2,787 $2,117 $8,192
$6,705 Cost of revenue 1,054 852 3,055 2,681 Gross profit 1,733
1,265 5,137 4,027 Operating expenses 1,794 1,424 5,089 4,332
Operating income (loss) (61) (159) 48 (305) Net income (loss) $(49)
$(154) $87 $(297) Basic/diluted net income (loss) per share $(0.01)
$(0.02) $0.01 $(0.05) ENCISION INC. Condensed Balance Sheets
(Unaudited) (Amounts in thousands) December 31, March 31, 2006 2006
Cash and cash equivalents $1,150 $902 Current assets 3,959 3,325
Total assets 4,469 3,817 Current liabilities 1,449 1,085
Shareholders' equity 3,020 2,732 Total liabilities and
shareholders' equity $4,469 $3,817 DATASOURCE: Encision Inc.
CONTACT: Marcia McHaffie of Encision Inc., +1-303-444-2600, Web
site: http://www.encision.com/
Copyright
Grafico Azioni Encision (AMEX:ECI)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Encision (AMEX:ECI)
Storico
Da Giu 2023 a Giu 2024